Royalty Report: Drugs, Cancer, Disease – Collection: 257617

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Delivery
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 257617

License Grant
This amendment addresses new parent for Licensor, territories and royalties.

With the original agreement, Licensors intellectual property, Licensor grants the Licensee of China an exclusive right and license under Licensors Intellectual Property applicable to the Licensed Product to develop, manufacture, market, sell, use, offer for sale and import the Licensed Product in the Territory during the term of this Agreement.

Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.

License Property
Licensor has intellectual property relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 4:6,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Field of Use
Irinotecan is used as a chemotherapy drug.
MM-398 is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. MM-398 recently achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer.

IPSCIO Record ID: 257476

License Grant
For Licensors intellectual property, Licensor grants the Licensee of China an exclusive right and license under Licensors Intellectual Property applicable to the Licensed Product to develop, manufacture, market, sell, use, offer for sale and import the Licensed Product in the Territory during the term of this Agreement.

Licensor grants the right of access, the right of reference and the right to use and incorporate all information provided to Licensee pursuant to obtaining the regulatory approval of the Licensed Product within the Territory and in performing the development, commercialization and all Licensees obligations in respect of the Licensed Product under this Agreement.

License Property
Licensor has intellectual property relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 4:6,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Irinotecan is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Irinotecan is used to treat cancers of the colon and rectum. It is usually given with other cancer medicines in a combination chemotherapy.

Field of Use
Irinotecan is used as a chemotherapy drug.

IPSCIO Record ID: 257586

License Grant
This amendment reflects the new parent of the Licensor, re-assignment of a sublicense, territories and royalties.

Licensor of Bermuda and its Parent, the Licensee, desire to amend the Agreement to transfer back to Licensor the right to develop and commercialize the Licensed Product in certain countries in Asia.   The original agreement was exclusive.

License Property
The Licensor has rights relating to liposomal irinotecan.

Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 4:6,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof.

The patents are for Liposomes Useful for Drug Delivery.

Field of Use
Liposomal irinotecan is used in chemotherapy.

IPSCIO Record ID: 257477

License Grant
The Licensor of China assigns and transfers to the SubLicensee of Bermuda all of Licensors rights and obligations under the License Agreement.

Licensor grants:
—  an exclusive right and license under the Licensors Licensed Technology and rights to the Joint Technology, to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, have sold, import and export the Licensed Compound and the Licensed Product in the Field outside the Licensor Territory; provided that Licensor reserves the right to conduct Development activities outside the Licensor Territory solely to support the Development and Commercialization of Licensed Compound and Licensed Products inside the Licensor Territory, and manufacture Licensed Compound and Licensed Products outside the Licensor Territory solely for use and distribution within the Licensor Territory; and,

— a non-exclusive right and license in the Field in the Licensor Territory under the Licensor Licensed Technology and rights to the Joint Technology, to the extent necessary for SubLicensee to perform its obligations under the Development Plan, and to Develop and manufacture the Licensed Compound and the Licensed Product in the Licensor Territory solely in support of Development and Commercialization of the Licensed Compound and the Licensed Product outside the Licensor Territory.

Previously, the development and commercialization rights to MM-398 in Europe and Asia had been licensed to Licensor. Sublicensee held the rights to the product in North America and all other territories around the world. Through this agreement, the worldwide rights to MM-398 have been reunited, with SubLicensee now having the right to develop and commercialize MM-398 in all territories of the world with the exception of Taiwan, where Licensor will retain its rights to develop and commercialize MM398.

License Property
MM-398 is a highly stable nanoliposomal formulation of irinotecan.  MM-398, or irinotecan, is used with chemotherapy treatments.

The property of the original agreement which is being reassigned with this agreement is:
Intellectual property relating to liposomal irinotecan;  Product shall mean any pharmaceutical composition comprising liposomally encapsulated Irinotecan (( + )-(S)-4, 11-Diethyl-4, 12-dihydro-4-hydroxy-3, 14-dioxo-1 Hpyrano[3, 4:6,7)indolizino[L2-b]chinolin-9-yl[l,4 -bipiperidin el-1- carboxylate, CAS 97682-44-5). including salts thereof;  and,  patents for Liposomes Useful for Drug Delivery.

Field of Use
Field means all human and veterinary fields of use, including therapeutic, prophylactic, palliative and diagnostic uses in all possible indications.   MM-398, or irinotecan, is used with chemotherapy treatments.

IPSCIO Record ID: 257475

License Grant
This amendment, between the Licensor of China and Licensee of Bermuda, clarifies term and modifies sublicensing royalties.  Under the original agreement, the Licensor of China assigns and transfers to the SubLicensee of Bermuda all of Licensors rights and obligations under the License Agreement.   The original agreement has conditional exclusivity.
License Property
The original agreement  licensed property is MM-398 is a highly stable nanoliposomal formulation of irinotecan.

The FDA has approved MM-398 (irinotecan liposome injection; Onivyde) in combination with 5-fluorouracil (5-FU) and leucovorin as a treatment for patients with metastatic pancreatic cancer following prior administration of a gemcitabine-based regimen.

Field of Use
The original agreement Field means all human and veterinary fields of use, including therapeutic, prophylactic, palliative and diagnostic uses in all possible indications.  MM-398, or irinotecan, is use with chemotherapy treatments.

IPSCIO Record ID: 27226

License Grant
We signed a licensee agreement to develop and commercialize liposome encapsulated doxorubicin (LED), liposome compounds worldwide.

LED allows cancer Phase I Breast, Prostate, 2 Patents patients to tolerate higher completed, Hematological dosages of chemotherapy initiated providing greater therapeutic Phase II in value in a number of types of June 1998 cancer tumors; liposome products consist of spheres of sub cellular size composed primarily of phospholipids, certain of which are the primary components of living cell membranes, and can be made to contain and deliver drugs.  This membrane encapsulation feature of liposome enables the entrapped drug to be circulated in the bloodstream in higher concentrations for longer periods of time than the free drug – clinical trial.  Pursuant to the license agreement, the Licensee agreed to assume all further responsibility for, and the costs associated with, the further development and testing of LED and LEP and the obtaining of all regulatory approvals.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.